YH42946
Phase 1/2Recruiting 2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC (Non-small Cell Lung Cancer)
Conditions
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Trial Timeline
Oct 2, 2024 → Jul 29, 2028
NCT ID
NCT06616766About YH42946
YH42946 is a phase 1/2 stage product being developed by Yuhan for NSCLC (Non-small Cell Lung Cancer). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06616766. Target conditions include NSCLC (Non-small Cell Lung Cancer), Solid Tumor.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC (Non-small Cell Lung Cancer) were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06616766 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in NSCLC (Non-small Cell Lung Cancer)